Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients
Open Access
- 1 April 2012
- journal article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 188 (7), 3532-3541
- https://doi.org/10.4049/jimmunol.1103693
Abstract
The CD20 mAb ofatumumab (OFA) induces complement-mediated lysis of B cells. In an investigator-initiated phase II trial of OFA plus chemotherapy for chronic lymphocytic leukemia (CLL), OFA treatment promoted partial CLL B cell depletion that coincided with reduced complement titers. Remaining CLL B cells circulated with bound OFA and covalently bound complement breakdown product C3d, indicative of ongoing complement activation. Presumably, neither complement- nor effector cell-based mechanisms were sufficiently robust to clear these remaining B cells. Instead, almost all of the bound OFA and CD20 was removed from the cells, in accordance with previous clinical studies that demonstrated comparable loss of CD20 from B cells after treatment of CLL patients with rituximab. In vitro experiments with OFA and rituximab addressing these observations suggest that host effector mechanisms that support mAb-mediated lysis and tumor cell clearance are finite, and they can be saturated or exhausted at high B cell burdens, particularly at high mAb concentrations. Interestingly, only a fraction of available complement was required to kill cells with CD20 mAbs, and killing could be tuned by titrating the mAb concentration. Consequently, maximal B cell killing of an initial and secondary B cell challenge was achieved with intermediate mAb concentrations, whereas high concentrations promoted lower overall killing. Therefore, mAb therapies that rely substantially on effector mechanisms subject to exhaustion, including complement, may benefit from lower, more frequent dosing schemes optimized to sustain and maximize killing by cytotoxic immune effector systems.Keywords
This publication has 52 references indexed in Scilit:
- Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphismBlood, 2011
- Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B CellsThe Journal of Immunology, 2011
- Complement: a key system for immune surveillance and homeostasisNature Immunology, 2010
- Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell MalignanciesJournal of Clinical Oncology, 2010
- Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemiaHaematologica, 2009
- B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcomeBlood, 2009
- Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximabLeukemia Research, 2008
- Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodiesCurrent Opinion in Immunology, 2008
- Serial Killing of Tumor Cells by Human Natural Killer Cells – Enhancement by Therapeutic AntibodiesPLOS ONE, 2007
- Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximabBlood, 2006